IDXX

IDEXX Laboratories has delivered a 28.4% gain over the past three years, yet its recent share price swings and shifting expectations now put the spotlight squarely on one question.

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report its earnings on Monday, November 2, 2026. The company has a market value of about $45.5 billion.

Is ZTS a good stock to buy? We came across a bullish thesis on Zoetis Inc. on D Invests’s Substack.

Get a deeper insight into the potential performance of Idexx (IDXX) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.

Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on IDXX.

IDEXX Laboratories (IDXX) drew fresh attention after Jefferies reiterated its Buy rating while cutting two animal health peers on pricing concerns, and highlighted diagnostics as relatively better insulated within the broader veterinary and livestock market.

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).